- Home
- SNCY vs AKBA Comparison
SNCY vs AKBA Comparison
Compare SNCY & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCY
- AKBA
- Stock Information
- Founded
- SNCY 1982
- AKBA 2007
- Country
- SNCY United States
- AKBA United States
- Employees
- SNCY N/A
- AKBA N/A
- Industry
- SNCY Air Freight/Delivery Services
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- SNCY Consumer Discretionary
- AKBA Health Care
- Exchange
- SNCY Nasdaq
- AKBA Nasdaq
- Market Cap
- SNCY 644.3M
- AKBA 669.7M
- IPO Year
- SNCY 2021
- AKBA 2014
- Fundamental
- Price
- SNCY $11.58
- AKBA $3.03
- Analyst Decision
- SNCY Buy
- AKBA Strong Buy
- Analyst Count
- SNCY 7
- AKBA 4
- Target Price
- SNCY $17.43
- AKBA $6.63
- AVG Volume (30 Days)
- SNCY 864.4K
- AKBA 5.0M
- Earning Date
- SNCY 05-01-2025
- AKBA 05-08-2025
- Dividend Yield
- SNCY N/A
- AKBA N/A
- EPS Growth
- SNCY N/A
- AKBA N/A
- EPS
- SNCY 0.98
- AKBA N/A
- Revenue
- SNCY $1,090,905,000.00
- AKBA $184,909,000.00
- Revenue This Year
- SNCY $6.72
- AKBA $21.58
- Revenue Next Year
- SNCY $10.37
- AKBA $47.69
- P/E Ratio
- SNCY $11.80
- AKBA N/A
- Revenue Growth
- SNCY 2.24
- AKBA N/A
- 52 Week Low
- SNCY $8.10
- AKBA $0.80
- 52 Week High
- SNCY $18.59
- AKBA $3.14
- Technical
- Relative Strength Index (RSI)
- SNCY 51.86
- AKBA 71.68
- Support Level
- SNCY $10.88
- AKBA $2.76
- Resistance Level
- SNCY $11.96
- AKBA $3.14
- Average True Range (ATR)
- SNCY 0.47
- AKBA 0.15
- MACD
- SNCY -0.02
- AKBA 0.02
- Stochastic Oscillator
- SNCY 34.14
- AKBA 86.08
About SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.